ONeil Trader
Vertex: Recent Clinical Setback Underscores The Need To Expand The Pipeline
Horizon Therapeutics: SEL-212 Data Confirms Krystexxa's Likely Dominant Position In Refractory Gout
Amicus Therapeutics: Inflection Point Coming In 2021
BioCryst Pharmaceuticals: Important Catalysts Could Drive Additional Upside In 2H 2020
BioNTech: Promising Early COVID-19 Data, But Still A Long Way To Go
Neos Therapeutics: Failure To Re-Launch
Coronavirus Roundtable: Preparing For The Months Ahead
Coronavirus Roundtable: Containing One's Reaction
Coronavirus Roundtable: Diagnosing The Market Situation
BioCryst Pharmaceuticals: BCX9930 Results In PNH Patients An Important Near-Term Catalyst
Acorda Therapeutics: Crisis Postponed, Inbrija Needs To Perform
Flexion Therapeutics: A Good Foundation For Growth In 2020
Apellis Pharmaceuticals: PEGASUS Trial Confirms Pegcetacoplan's Efficacy Over Soliris In PNH Patients
Acorda Therapeutics: Situation Getting Worse, Prompting A Restructuring
Retrophin: Thesis Falls Back To Sparsentan
Neos Therapeutics: ADHD Franchise Needs To Return To Prescription Growth
Achillion Pharmaceuticals: ACH-5228 De-Risking Gets Noticed
BioCryst Pharmaceuticals: Waiting For A Cash Infusion
Flexion Therapeutics: Zilretta's Uptake Improves
NovoCure: Good News On All Fronts
Ascendis Pharma Unveils The TransCon Oncology Pipeline
The Medicines Company: Limited Upside And A Tough Market Battle For Inclisiran
Acorda Therapeutics: Survival Mode
Amarin's Updated Guidance May Still Prove Conservative
Baozun: No Apparent Trade War Impact
Ra Pharmaceuticals Moves In The Right Direction
argenX Unveils 2 New Pipeline Candidates
LGI Homes: Community Expansion Accelerates, But Upside Seems Limited
Axsome Therapeutics: Assessing If There's Upside Left After Big Run
Achillion Pharmaceuticals Reports Positive PNH Data, But The Market Doesn't Care
Amicus Therapeutics: Galafold Doing Better Than Q1 Revenues Suggest
BioCryst Pharmaceuticals Is In A Very Tough Position After BCX7353 Phase 3 'Success'